According to the survey, two out of three plan or have ad hoc initiatives underway
Adherence to therapies is at the heart of the communication and information projects of pharmaceutical companies. In fact, two out of three have or are developing initiatives aimed at raising awareness of the importance of following the treatment with constancy and precision.
This is what emerges from a survey out of 200 companies (American 29.3% of the sample; multinationals 16%; European 36.2%; Asia-Pacific area 9.8%; Middle East/Africa 4%; South America 4.6%) conducted by 'Eyeforpharma'. Interviewees reported the use of management services, education projects and 'coaching' on adherence to care, all strictly on the Internet, as well as SMS reminders and ad hoc devices to help deal with the problem.
The data demonstrates that pharmaceutical companies are both clinically and financially motivated to address the issue: 97% of the managers surveyed believe that lack of adherence primarily affects patient outcomes, but 84% indicates that there is also a significant impact on the revenues of the companies themselves. And while perfect fit is clearly not possible, respondents' 87% believe it could be improved by at least the 10%.
If this improvement were achieved, analysts calculate that it would boost the companies' sales by an amount equivalent to the entire Japanese market. According to the research, this can only happen by exploiting the potential of new technologies (the 72% of companies are convinced of this), in which there is a strong willingness to invest: 2 out of 3 respondents expect a growth in funds over the next three years , with 20% predicting an increase greater than 50% from current levels.
Barbara Di Chiara – 5 May 2015 – PharmaKronos
Related news: I don't treat myself and the doctor doesn't know it. Poor adherence to therapies
